(Q45259881)

11 December 2017

A randomized controlled trial of acarbose in hepatic encephalopathy (English)

1 reference

randomized controlled trial

11 December 2017

1 reference

Sandro Gentile

1

1 reference

11 December 2017

Giuseppina Guarino

2

1 reference

11 December 2017

Marco Romano

3

1 reference

11 December 2017

Ivo A Alagia

4

1 reference

11 December 2017

Maura Fierro

5

1 reference

11 December 2017

Stefano Annunziata

6

1 reference

11 December 2017

Paolo L Magliano

7

1 reference

11 December 2017

Antonietta G Gravina

8

1 reference

11 December 2017

Roberto Torella

9

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Clinical Gastroenterology and Hepatology

11 December 2017

1 reference

11 December 2017

3

1 reference

11 December 2017

2

1 reference

11 December 2017

184-191

1 reference

Pathogenesis and treatment of portal-systemic encephalopathy: an update

11 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Blood and brain concentrations of mercaptans in hepatic and methanethiol induced coma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Increased intestinal hydrolysis of urea in patients with alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Lactobacillus acidophilus (Enpac) in Treatment of Hepatic Encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Glucose tolerance and diabetes in chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Incidence of altered glucose tolerance in liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Alterations of glucose metabolism in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in man

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

C-peptide and Insulin in Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Interindividual variability of the number connection test

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Safety Profile of Acarbose, an α-Glucosidase Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Hepatic injury caused by acarbose

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Acarbose-induced acute severe hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Drug-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

Aminotransferase activity and acarbose treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900667-6

7 January 2021

10.1016/S1542-3565(04)00667-6

Identifiers

DOI

1 reference

11 December 2017

1 reference